We then developed peptides based on the strategy to disrupt USP25‐SHLD2 binding and demonstrated that the combination of the peptide with chemotherapeutic drug increases killing efficiency in colon cancer cells and PDX model, which implies a potential therapy strategy to increase chemotherapy sensitivity and achieve improved outcomes (refer to Figure 8). This evidence concerns the gene SHLD2 and malignant colon neoplasm.